NASDAQ:OPTNOptiNose Stock Price, Forecast & News

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPTN shares have increased by 4.7% and is now trading at $5.30.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OptiNose.

OptiNose is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for OptiNose.

OptiNose Inc (NASDAQ:OPTN) issued its earnings results on Tuesday, August, 4th. The company reported ($0.56) earnings per share for the quarter, meeting the consensus estimate of ($0.56). OptiNose had a negative net margin of 265.88% and a negative return on equity of 282.14%.
View OptiNose's earnings history.

4 Wall Street analysts have issued twelve-month target prices for OptiNose's shares. Their forecasts range from $17.00 to $25.00. On average, they expect OptiNose's stock price to reach $20.50 in the next year. This suggests a possible upside of 286.8% from the stock's current price.
View analysts' price targets for OptiNose.

Media headlines about OPTN stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OptiNose earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about OptiNose.

OptiNose saw a drop in short interest in January. As of January 15th, there was short interest totaling 7,980,000 shares, a drop of 10.6% from the December 31st total of 8,930,000 shares. Based on an average daily volume of 270,900 shares, the short-interest ratio is currently 29.5 days. Approximately 36.5% of the company's shares are short sold.
View OptiNose's Short Interest.

Some companies that are related to OptiNose include Akcea Therapeutics (AKCA), Kura Oncology (KURA), Kiniksa Pharmaceuticals (KNSA), Arvinas (ARVN), Arcus Biosciences (RCUS), Constellation Pharmaceuticals (CNST), Karyopharm Therapeutics (KPTI), Theravance Biopharma (TBPH), Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Nabriva Therapeutics (NBRV), Akero Therapeutics (AKRO), I-Mab (ARQT), Enanta Pharmaceuticals (ENTA) and Stoke Therapeutics (STOK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Proteostasis Therapeutics (PTI), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Matinas BioPharma (MTNB), Flexion Therapeutics (FLXN), Idera Pharmaceuticals (IDRA), Paratek Pharmaceuticals (PRTK), Dynavax Technologies (DVAX), SCYNEXIS (SCYX) and Selecta Biosciences (SELB).

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose's stock is owned by a number of retail and institutional investors. Top institutional investors include Thrivent Financial for Lutherans (3.71%), Wasatch Advisors Inc. (2.02%), Paradigm Capital Management Inc. NY (1.62%), Hudson Bay Capital Management LP (0.43%), Bank of America Corp DE (0.32%) and Bank of New York Mellon Corp (0.31%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs.
View institutional ownership trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Wasatch Advisors Inc., Marshall Wace LLP, Hudson Bay Capital Management LP, Bank of New York Mellon Corp, UBS Group AG, and First Republic Investment Management Inc.. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp,, Peter K Miller, and Ramy A Mahmoud.
View insider buying and selling activity for OptiNose.

OPTN stock was bought by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY, PDT Partners LLC, Bank of America Corp DE, California Public Employees Retirement System, SG Americas Securities LLC, State of Wisconsin Investment Board, ProShare Advisors LLC, and Aigen Investment Management LP. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, and Thomas Edward Gibbs.
View insider buying and selling activity for OptiNose.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPTN stock can currently be purchased for approximately $5.30.

OptiNose has a market capitalization of $243.76 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe.

The official website for OptiNose is www.optinose.com.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]